Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy

Inclusion Criteria:

• Older than 20 years old and younger than 80 years old
• Pathologically confirmed pancreatic ductal adenocarcinoma (metastatic or locally advanced stage)
• ECOG Performance status ≤2
• Scheduled fot concurrent chemoradiation
• Adequate liver function (total bilirubin < 1.5 X the upper limits of normal (ULN), AST and ALT <3 X UNL, and alkaline phosphatases < 3 X ULN or < 5 x ULN in case of liver involvement)
• Adequate BM function (WBC ≥ 3,500/µl, absolute neutrophil cell count ≥ 1,500 /µl, platelet count ≥ 100,000/µl)
• Not remarkable coagulation profile (PT < 1.5 international normalized ratio(INR), aPTT <35 sec)
• Subjects who given written informed consent after being given a full description of the study

Exclusion Criteria:

• Coexisting of other malignancies within 5 years, except squamous cell carcinoma and basal cell carcinoma of the skin
• Evidence of distant metastasis, such as liver, peritoneum and brain
• history of receiving the chemoradiation for pancreatic cancer in the other hospital
• History of receiving the operation which affect the anatomy of upper gastrointestinal tract
• Any trouble for examination of upper endoscopy
• Evidence of GI ulcers (A1~H2) on endoscopy before start of chemoradiotherapy.
• Use of aspirin, anti-platelet agent, anticoagulation agent, NSAIDs, or glucocorticoid within 1 week or enable to stop the administration (including start during chemoradiation)
• Use of PPI, Histamine-2 receptor antagonist, antacid, prostaglandin, sucralfate within 2 weeks or enable to stop the administration
• Patients who are unwilling or unable to provide informed consent, such as those with psychiatric problem, drug abuse or alcoholism